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1- SUMMARY 
BACKGROUND 
Dual antiplatelet therapy is recommended in patients undergoing primary 
percutaneous coronary intervention (p-PCI) for ST-segment elevation myocardial 
infarction (STEMI). In the past few decades, oral antiplatelet agents have proved to 
significantly reduce the incidence of ischemic events in patients with 
atherothrombotic diseases. Nevertheless, recurrent ischemic events often occur in 
patients undergoing stent implantation. High platelets reactivity has been associated 
with a higher risk for major cardiovascular events in patients with acute coronary 
syndromes (ACS). Several pre-analytical variables may influence platelet function 
analysis. The aim of our study was to assess the on-treatment platelet reactivity in 
peripheral and coronary blood, in a group of patients receiving dual antiplatelet 
therapy undergoing primary percutaneous coronary intervention (p-PCI) for 
STEMI. 
 
METHODS 
Eligible patients for the study were considered as consecutively admitted 
patients to the emergency department of University-Hospital of Padua with a 
diagnosis of ACS with ST-segment elevation scheduled for an urgent procedure of 
coronary angioplasty. One hundred nine patients who consecutively underwent p-
PCI (males: 72%, females: 28%; mean age: 64±13 years) were enrolled. Before the 
coronary angioplasty intervention, the patients were treated with dual antiplatelet 
therapy (aspirin 250mg I.V in association with one another oral thienopyridines; 
Clopidogrel 300/600mg, Prasugrel 60 mg or Ticagrelor 180 mg) and with 
anticoagulant therapy (unfractionated heparin 70U/Kg I.V). During the coronary 
angioplasty intervention two different samples were obtained, one from peripheral 
artery and the other from coronary blood. The platelet aggregation was studied 
using the impedance aggregometry Multiplate®, according to manufacturer’s 
indications. For each patient the values of “Area Under the Curve” (AUC) in ADP-
test and ASPI-test were considered, both in the peripheral and in coronary blood. 
		
	
6	
“Low responders of antiplatelet therapy” were considered when an AUC value of 
ASPI-test or ADP-test greater than or equal to a pre-established cut-off. 
RESULTS 
The Multiplate® analysis of ADP-test revealed that mean values were 
slightly higher in peripheral blood compared to coronary blood (peripheral blood: 
41±28 U; coronary blood: 39±28 U), However these values with no statistically 
significant difference (p=0.68). Likewise, for the ASPI-test; no statistically 
significant difference between the mean values in the peripheral blood compared to 
the coronary blood (peripheral blood: 23±4 U; coronary blood: 17±2 U; p=0.06).  
The percentage of low-responders to ADP-receptor inhibitors was 
significantly greater than the percentage of low-responders to acetylsalicylic acid 
at time of primary PCI both in the peripheral and in the coronary blood samples 
(peripheral ADP-test: 38%; peripheral ASPI-test: 14%; p<0.01, Coronary ADP-
test: 36%; coronary ASPI-test: 11%; p<0.01). In peripheral blood, the prevalence 
of “low Clopidogrel responders” was higher (45%) than that observed for Prasugrel 
(36%) and Ticagrelor (33%). Similar results were observed in coronary blood, the 
prevalence of “low Clopidogrel responders” was higher (40%) than that observed 
for Prasugrel (36%) and Ticagrelor (29%) however these results were with no 
significant statistical difference (p >0.05). Finally, a positive and statistically 
significant linear correlation was observed for both ASPI-test and ADP-test in 
peripheral and coronary blood (r2 0.23, p <0.001 and r2 0.12, p <0.001; 
respectively). That means; those who are resistant to acetylsalicylic acid tend to be 
resistant to ADP receptor inhibitors, and vice versa; those who are sensitive to 
acetylsalicylic acid therapy tend to be sensitive to ADP inhibitor therapy also. Our 
observed data did not show a correlation between platelet function and clinical 
outcome both for in-hospital and 1-year clinical outcomes. 
 
CONCLUSIONS 
In this study we observed that the overall platelet reactivity in coronary blood 
is lower than in peripheral blood, though not statistically significant. This more 
likely appears to be due to high antiplatelet drugs effect at plaque 
ulceration/thrombus site, where the hemostatic process is highly active at onset of 
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STEMI. Larger studies are needed for better evaluation of these mechanisms in term 
of pharmacodynamic, pharmacokinetic and receptor kinetic properties of 
antiplatelet agents.	
The other interesting result emerging from data processing is the high incidence 
(about 30%) of low response to thienopyridine type antiplatelet drugs at the time of 
primary angioplasty. This result, moreover known for Clopidogrel in addition  our 
results include patients treated with Prasugrel and Ticagrelor also. An explanation 
of this phenomenon which also involves potent recent drugs, requires careful 
analysis and further studies. The significant direct correlation between platelet 
reactivity in peripheral and in coronary blood is still a matter of debate. Larger 
studies are needed for in-depth assessment of any correlation between on–treatment 
platelet reactivity measured in coronary blood and clinical outcome.	  
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2- RIASSUNTO 
INTRODUZIONE 
La doppia terapia antiaggregante (DAPT) è raccomandata in pazienti 
sottoposti ad intervento di angioplastica coronarica primaria (p-PCI) per infarto 
miocardico acuto con sopraslivellamento del tratto ST (STEMI). Infatti, il 
trattamento con farmaci antipiastrinici orali ha dimostrato di ridurre 
significativamente l'incidenza di eventi ischemici nei pazienti con malattie 
aterotrombotiche sia in fase acuta che in fase cronica.	Tuttavia, spesso si verificano 
eventi ischemici ricorrenti nei pazienti sottoposti ad angioplastica ed impianto di 
stent. È stato dimostrato che una delle cause di recidiva ischemica sia l’elevata 
reattività delle piastrine. Pertanto, lo studio della funzione piastrinica diventa un 
elemento sempre più importante per valutare questo tipo di pazienti. Diverse 
variabili pre-analitiche possono influenzare l'analisi della funzione piastrinica. Lo 
scopo del nostro studio è stato quello di valutare la reattività piastrinica del sangue 
periferico e coronarico in un gruppo di pazienti trattati con DAPT e sottoposti p-
PCI per STEMI. 
 
METODI 
Abbiamo considerato eleggibili allo studio tutti i pazienti consecutivamente 
giunti in urgenza al Pronto Soccorso dell’Azienda Ospedaliera di Padova con 
diagnosi di sindrome coronarica acuta con sopraslivellamento del tratto ST per i 
quali fosse indicata l’esecuzione in urgenza di una procedura di angioplastica 
coronarica. Sono stati arruolati 109 pazienti (maschi: 72%, femmine: 28%; età 
media: 64±13 anni). I pazienti arruolati nello studio sono stati trattati, prima di 
essere sottoposti alla procedura di angioplastica primaria, con doppia terapia 
antiaggregante (aspirina 250 mg e.v in associazione con uno dei seguenti tre 
farmaci: Clopidogrel 300/600 mg per os, Prasugrel 60 mg per os o Ticagrelor 180 
mg per os) e con terapia anticoagulante (eparina non frazionata 70 U/Kg e.v). 
Durante la procedura di angioplastica primaria sono stati eseguiti due tipi di 
prelievo, uno dal sangue arterioso periferico ed uno dal sangue arterioso coronarico. 
L’aggregazione piastrinica è stata studiata con l’aggregometro Multiplate® 
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secondo le indicazioni fornite dal costruttore. Per ogni paziente sono stati valutati i 
valori di “Area Under the Curve” (AUC) nell’ADP-test e nell’ASPI-test, ottenuti 
sul sangue periferico e sul sangue coronarico. “Low responders alla terapia 
antiaggregante” sono stati definiti quei pazienti con valori di “Area Under Curve” 
(AUC) all’ASPI test o all’ADP test sono maggiore o uguale a un range prestabilito. 
 
RISULTATI 
Non abbiamo osservato differenza statisticamente significativa tra i valori 
medi di ADP-test calcolati su sangue periferico e su sangue coronarico. I valori 
medi delle AUC sono risultati lievemente superiori nel sangue periferico che nel 
sangue coronarico (sangue periferico: 41±28 U; sangue coronarico: 39±28 U; 
p=0.68). Allo steso modo, non è stata riscontrata differenza statisticamente 
significativa tra i valori medi di ASPI-test calcolati su sangue periferico e su sangue 
coronarico. Anche in questo caso abbiamo osservato valori medi di AUC 
lievemente superiori nel sangue periferico che nel sangue coronarico (sangue 
periferico: 23±4 U; sangue coronarico: 17±2 U; p=0.06). Sia nel sangue periferico 
che nel sangue coronarico la percentuale di pazienti “low responders” al 
trattamento con inibitori del recettore per l’ADP è risultata essere statisticamente 
superiore alla percentuale di pazienti “low responders” alla terapia con acido 
acetilsalicilico al momento dell’angioplastica primaria (ADP-test periferico: 38%; 
ASPI-test periferico: 14%; p<0.01. ADP-test coronarico: 38%; ASPI-test 
coronarico: 11%; p<0.01). Nel sangue periferico la prevalenza di "low responders” 
al Clopidogrel era superiore (45%) a quella osservata rispettivamente per Prasugrel 
(36%) e Ticagrelor (33%). Risultati simili sono stati osservati nel sangue 
coronarico. In particolare, la prevalenza di "low responders” al Clopidogrel è stata 
superiore (40%) rispetto a quella osservata per Prasugrel (36%) e Ticagrelor (29%). 
Non è stata osservata alcuna differenza significativa (p> 0,05) nella prevalenza dei 
pazienti con valori di ADP-test superiori al cut-off prestabilito, considerando 
separatamente le tre diverse tienopiridine. Infine è stata individuata una 
correlazione lineare statisticamente significativa tra “low responders” all’acido 
acetilsalicilico e “low responders” agli inibitori del recettore dell’ADP. Questa 
osservazione indica come i pazienti resistenti al trattamento con acido 
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acetilsalicilico tendono ad essere resistenti anche al trattamento con inibitori del 
recettore per l’ADP e, viceversa, pazienti “sensibili” alla terapia con acido 
acetilsalicilico tendono ad essere “sensibili” anche al trattamento con inibitori del 
recettore per l’ADP. Questi resultati sono stati osservati sia su sangue periferico (r2 
0.23, p<0.001) che su sangue coronarico (r2 0.12, p<0.001). I dati che abbiamo 
osservato non mostrano un’associazione tra funzione piastrinica e outcome clinico 
nè per quanto riguarda gli “in-hospital outcome” né per quanto riguarda gli 
outcome a distanza di 1 anno. 
 
CONCLUSIONI 
I dati analizzati ci hanno permesso di dimostrare che la reattività piastrinica nel 
sangue coronarico era inferiore rispetto a quella osservata nel sangue periferico. 
Sembrerebbe quindi che, la risposta alla terapia farmacologica con doppia 
antiaggregante prima della procedura sia maggiore proprio laddove il processo 
emostatico è più attivo, ossia a livello della placca aterosclerotica sede della 
formazione del trombo responsabile dell’insorgenza della STEMI. Questo 
meccanismo necessità di conferma in termini di farmacodinamica, farmacocinetica 
e di cinetica recettoriale. L’altro dato estremamente interessante emerso 
dall’elaborazione dei dati è l’elevata incidenza (circa 30%) dei pazienti “low 
responders” al trattamento con farmaci antiaggreganti di tipo tienopiridinico al 
momento della angioplastica primaria. Questo risultato, peraltro noto per il 
Clopidogrel, comprende anche pazienti trattati con Prasugrel e Ticagrelor. Una 
possibile spiegazione di questo fenomeno, che coinvolge anche i farmaci di 
“seconda generazione”, necessita di un’attenta analisi. Abbiamo infine osservato 
una significativa correlazione tra reattività piastrinica nel sangue periferico e nel 
coronario. I nostri risultati, che alla luce dei limiti del nostro lavoro devono 
considerarsi come preliminari, necessitano di essere confermati su casistiche più 
numerose soprattutto per quanto riguarda la correlazione tra “on-treatment platelet 
reactivity” misurata nel sangue coronarico e outcomes clinici.	 	
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3- BACKGROUND 
        1- Pathogenesis of acute coronary syndrome in patients with ST-Elevation 
Myocardial Infarction. 
Atherosclerotic plaque rupture or erosion and subsequent thrombus 
formation constitute the principal mechanisms leading to vessel occlusion in acute 
ST-elevation myocardial infarction (STEMI) (1-4). In fact, plaque rupture is by far 
the most frequent cause of arterial thrombosis, accounting for approximately 75% 
of coronary thrombi leading to myocardial infarction or death (5-7). Exposure of 
the thrombogenic lipid-rich core in plaque rupture may lead to thrombosis, which 
covers the rupture site and extends into the lumen (8). Inflammation and increased 
oxidative stress play important roles in the pathogenesis of atherosclerosis and 
plaque instability (9, 10). Several studies have focused on the platelet and/or fibrin 
component of coronary thrombi (11-13), and tissue factor has also been reported to 
be involved in the pathogenesis of atherosclerosis by promoting thrombus 
formation (14-17). Coronary thrombi developed as consequence of plaque erosion 
or rupture, are dynamic and usually evolve in stages (18-24). When the thin fibrous 
cap of atherosclerotic plaque is disrupted, collagen and tissue factor become 
exposed to flowing blood, which triggers for accumulation and activation of 
platelets promoting conversion of fibrinogen to fibrin, thereby initiating thrombus 
formation (9). Initially, platelets aggregate in the lipid core, and the thrombus 
begins to protrude into the lumen. The thrombus grows in association with the 
formation of a fibrin network until the entire vessel is eventually occluded. Fibrin 
may accumulate over the plaque, stabilizing the thrombus and entraping large 
numbers of erythrocytes and inflammatory cells, finally forming a red thrombus. 
The erythrocyte-rich thrombus in this final stage may propagate proximally and 
distally after the onset of STEMI (9).  
The presence of an intracoronary thrombus at the culprit lesion site may 
increase the risk of distal embolization (DE), resulting in larger myocardial 
necrosis, microvascular damage and worse residual left ventricular function during 
primary percutaneous coronary intervention (p-PCI) (25-29). In the last decades, 
different aspiration thrombectomy and distal protection devices have been 
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developed in order to limit distal embolization during p-PCI. The evidences coming 
from many studies involving these devices provided conflicting results in terms of 
myocardial salvage and clinical outcome. However, the increased use of thrombus-
aspiration in p-PCI has enabled the unique opportunity of antemortem evaluation 
of composition, architecture and dynamic process of coronary artery thrombi (9).    
The histopathological evaluations of aspirated intracoronary thrombi 
obtained from STEMI patients have shown heterogeneity in composition, 
architecture and chrono-biology of coronary thrombosis. (30-34). In particular, the 
early studies, investigating intracoronary thrombi obtained from STEMI patients 
within 6 hours of symptom onset by light microscopy, found that 50% of the 
thrombi were days or weeks old, before symptomatic presentation of infarct (30), 
indicating that plaque disruption and thrombus formation occur significantly earlier 
than the onset of symptoms (32). Moreover, Nagata et al. demonstrated that the 
dominant cell type of thrombi in the early phase of STEMI was platelets and that 
large thrombi contained more erythrocytes (31). Moreover, erythrocyte-rich 
thrombi contained more inflammatory cells and reflected high thrombus burden, 
resulting in impaired electrocardiographic and angiographic myocardial 
reperfusion and progression of LV remodeling (35). More recently, it has been 
demonstrated, by mean of electron microscopy, that the fibrin content increased in 
association with the ischemic time, whereas the platelet content decreased (36, 37), 
indicating that ischemic time was a powerful predictor of thrombus composition. 
Furthermore, thrombus structure clearly appeared to rapidly evolve with respect of 
ischemic time, paralleling in vivo animal studies, showing that in the very early 
stage of thrombus formation, just after endothelial injury, its structure is primary 
composed of activated platelets and rapidly stabilized by fibrin fibers with 
decreasing proportion of platelets over time (38, 39). 
Taking together, all these observations reflect the fact that aspirated thrombi 
may be older than expected based on the duration of the ischemic time and indicate 
that partial vessel occlusion leading to acute coronary syndromes (ACS) frequently 
occurs days or weeks before symptom onset. In addition, another study including 
STEMI patients presenting within 12 hours of symptom onset revealed three 
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patterns of aspirated coronary thrombi: 1) platelet-rich, low-erythrocyte thrombi, 2) 
platelet and erythrocyte-mixed thrombi and 3) erythrocyte-rich, low-platelet 
thrombi. These three types were observed despite a similar time from symptom 
onset to reperfusion among the three groups (35). These findings suggest that 
thrombus components may be dependent on not only by ischemic time, but also by 
multiple factors influencing inflammation, oxidative stress and blood viscosity. 
There are some reports related to coronary thrombus and plaque morphology. The 
first one reported that fibrin was more abundant than platelets in the thrombi of 
ruptured plaques, whereas platelets tended to be more abundant than fibrin in the 
thrombi of eroded plaques (11). The second report was on the relationship between 
thrombus age classified as early (<1 day) or late characterized in phases of lytic (1 
to 3 days), infiltrating (4 to 7 days) or healing (>7 days) and plaque morphology in 
sudden coronary death victims (40). The results showed that late-stage thrombi 
were present in the 69% of the culprit plaques and that the majority of early thrombi 
(<1 day) and lytic thrombi (1 to 3 days) were present in plaque ruptures as compared 
with erosions, whereas the majority of thrombi in erosions were infiltrating (4 to 7 
days) or healing (>7 days) (40). The third study was a clinic-pathological study 
finding that the serum myeloperoxidase (MPO) levels were significantly higher in 
the patients with eroded plaques than in those with ruptured plaques (41). 
In atherosclerotic plaques, macrophages and smooth muscle cells produce 
large amounts of tissue factor that is the main trigger of the coagulation system. 
Moreover, abundant tissue factor is expressed in advanced atherosclerotic lesions 
(11, 42, 43). Therefore, plaque disruption leading to tissue factor exposure to 
flowing blood, triggers coagulation activation and initiates platelet-fibrin thrombus 
formation. It has been suggested that abundant tissue factor within plaque is the 
major factor responsible for the formation of large-size fibrin-rich thrombi and that 
local/systemic activation of monocytes increases the thrombogenic potential of the 
blood flow, thus leading to the onset of ACS (44). Recently, also microparticles 
(MPs) have been reported to play a crucial role in pathogenesis of atherosclerotic 
plaque. MPs: are 0.1-1-µm membrane vesicles that are released into the 
extracellular space following cell activation or apoptosis (45). Several studies have 
proposed that MPs may contribute to atherosclerotic plaque development and 
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thrombus formation/progression (46-49). In addition, human atherosclerotic 
plaques contain high levels of MPs, and a large number of human plaque MPs 
express CD40 ligand and harbor tissue factor, increasing their procoagulant activity 
(46). Human plaque MPs are reported to be significantly prothrombogenic because 
they generate twice as much thrombin as circulating MPs in the same patient (50). 
These heterogeneities in the coronary thrombus composition and microbiology 
could reflect the thrombogenicity properties of coronary plaques, differing in 
composition, location and inflammatory pathways status. 
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2- Antiplatelet therapy in patients with ST-Elevation Myocardial Infarction 
The main purpose to reduce myocardial necrosis is to restore coronary flow 
to the coronary culprit vessel as early as possible. When the clinical symptoms of 
STEMI occurred within the previous 12 hours and is associated with a persistent 
ST elevation or with a newly emerging left branch block, p-PCI must be done 
immediately, otherwise, thrombolytic therapy should be considered as alternative 
way of reperfusion (51). Several clinical evidences revealed a reduced mortality 
rate in patients undergoing primary angioplasty in centers that perform a high 
number of primary angioplasty procedures (52). 
Patients undergoing primary angioplasty should receive dual antiplatelet 
therapy (DAPT) in combination with a parenteral anticoagulant. In general, the 
most commonly used antiplatelet drugs are Aspirin, ADP receptor antagonists or 
thienopyridine (Ticlopidine, Clopidogrel and Prasugrel), glycoprotein (GP) IIb / 
IIIa antagonists (such as Abciximab, Eptifibatide and Tirofiban), PAR-1 
antagonists (SCH 530348 and 5555) and phosphodiesterase inhibitors 
(Dipyridamole, Dilostazol) (53) (Figure 1). 	
 
	Figure 1. Pathways of platelet activation and mechanism of action of 
antiplatelet agents. 
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2-1 Thromboxane A2 receptor inhibitor (Figure 1):  
In activated platelets, the phospholipase A2 produces thromboxane A2 
(TxA2) from arachidonic acid through a series of reactions including an initial step 
mediated by cyclooxygenase. Acetylsalicylic acid inhibits the cyclo-oxygenase 
enzyme in platelets that converts arachidonic acid into the prostaglandin 
endoperoxides PGG2 and PGH2; and thus, the subsequent conversion of these (via 
thromboxane synthase) to TxA2 (54). Three isoforms of cyclooxygenase have been 
recognized for activation of platelets: COX-1 isoform is expressed ubiquitously and 
constitutively isoform in larger quantities in platelets; COX-2 is an inducible form 
that is expressed in cells at inflammation sites; COX-3 denotes a variant of splicing 
of COX-1 (53).  
Acetylsalicylic acid, at low concentrations, inhibits irreversibly COX-1 and 
COX-3 but not COX-2. By this mechanism, aspirin inhibits platelet activation by 
reducing but not blocking the thromboxane A2 synthesis at the time of its action at 
COX-1 level (53). 
 
2-2 ADP receptor inhibitors (Figure 1):  
Another important category of antiplatelet drugs are the ADP receptor 
inhibitors, thienopyridines. There are three forms of ADP receptors in the platelets: 
P2Y1 and P2Y12 are involved in the aggregation as metabotropic ADP receptors, 
while an ionotropic P2X1 receptor of adenosine triphosphate receptor is involved in 
the calcium entry (53). Ticlopidine and Clopidogrel are pro-drugs, activated by 
cytochrome P450, that irreversibly inactivate P2Y12 type of ADP receptor through 
dose-dependent aggregation inhibition (53, 55). Ticlopidine is a very effective drug 
in inhibition of platelet aggregation but is often associated with side-effects, 
particularly neutropenia in some patients; for this reason, it has been largely 
replaced by Clopidogrel (53). Approximately 15% of Clopidogrel is activated by 
cytochrome P450, while the remaining part is hydrolyzed into inactivate derivatives 
in circulation by hepatic carboxylesterase (56).  
More recently ADP receptor inhibitors (Prasugrel and Ticagrelor) have been 
developed and always act at P2Y12 level of ADP receptor.  
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Prasugrel is administered as Clopidogrel in the inactive prodrug form and 
likewise irreversibly inhibits the P2Y12 receptor. However, Prasugrel, unlike 
Clopidogrel, is almost entirely transformed to its active form by allowing higher 
concentrations of active metabolites and better inhibition of P2Y12 receptor.  
Ticagrelor is a non-thienopyridine inhibitor of P2Y12 receptor; in contrast to 
others thienopyridine drugs, it is already administered orally as active drug and also 
produces a reversible inhibition of the P2Y12 receptor (56, 57). However, 
Ticagrelor, unlike Clopidogrel and Prasugrel, makes a reversible rather than 
irreversible inhibition of platelets function, which means that the drug can come off 
the receptor when treatment is curtailed and platelet function can be restored. 
 
2-3 Dual antiplatelet therapy 
Aspirin and ADP receptor antagonists act through independent and 
complementary mechanisms to inhibit platelet aggregation, and their combination 
has been proposed, particularly in patients with ACS who must undergo 
percutaneous coronary intervention (PCI). To date, the dual antiplatelet therapy 
with Aspirin and Clopidogrel represents the standard therapy for these patients, 
although recent studies have approved the use of either Prasugrel or Ticagrelor in 
combination with aspirin (57). 
Aspirin is administered orally at a dose of 150-300 mg to ensure complete 
inhibition of thromboxane A2 dependent platelet aggregation, but may also be 
administered intravenously (250-500 mg) in patients unable to swallow (51). 
Clopidogrel is conventionally administered as loading dose with 300 mg orally or 
preferably 600 mg, followed by 75 mg as maintenance dose (51); Prasugrel is 
administered orally with a loading dose of 60 mg and a maintenance dose of 10 mg; 
Ticagrelor is administered with a 180 mg oral dose and a maintenance dose of 90 
mg twice a day (51). 
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3- Study of platelet functional with Multiplate®, a new Point-of-Care 
(POC) technology. 
Platelet function can be evaluated by platelet aggregation induced by 
different agonists. Frst of all ADP, the target of thienopyridines (Ticlopidine, 
Clopidogrel, Prasugrel) and arachidonic acid, which is predominantly affected by 
Aspirin. The historical method for studying platelet function is represented by 
platelet-rich plasma aggregation. There are also many systems, so-called “Point-of 
-Care”, which allow the measurement of whole-blood platelet aggregation (58, 80). 
The different available methods to measure platelet function are reported in Table 
1.  
The majority of evidence in the field of on-treatment platelet reactivity to 
antiaggregant drugs refers to a very specific clinical setting: the acute phase of 
patients with acute coronary syndrome undergoing PCI with stent implantation. It 
was proposed cutoff values for high and low on-treatment platelet reactivity to 
antiplatelet drugs associated with post–percutaneous coronary intervention 
ischemic/bleeding events for various platelet function tests (PFTs). A relevant 
number of studies has shown that, in this clinical context, the presence of an ADP-
induced high on-treatment platelet reactivity (HPR) is associated with a 
significantly increased risk of ischemic events, in particular of stent thrombosis, 
cardiac death and MI (59-62, 80) both at early and late follow-up.  
Table 1. Laboratory methods of platelet funcion test. 
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3-1 Multiplate®analyzer.  
The Multiplate® is an instrument that is used for measuring and studying 
platelet aggregation based on the principles of impedance measurement (63). The 
use of “impedance” in the study of platelet aggregation was introduced by Cardinal 
and Flower, who elaborated an instrument equipped with two platinum electrodes 
that were immersed in the sample and on which it occurred platelet adhesion, result 
in growing the electrical resistance between the two electrodes (64). Changes in 
electrical impedance were recorded continuously and varied proportionally as 
platelets are attached to the electrodes. The main limit of this system was 
represented by the fact that the electrodes were reusable and had to be cleaned 
between tests and this was a possible source of error (63). To overcome 
contamination problem, a new instrument that uses disposable cuvettes 
(Multiplate® analyzer, Dynabyte Medical, Munich) was introduced. Within each 
cuvette, there are four sensors, thus giving rise to two independent measurements 
that increase the reliability of the test. In addition, the Multiplate® has five channels 
that allow to run up to five tests at the same time for about 10 minutes, which 
dramatically shortens the time (64). The Multiplate® is a computerized instrument 
Figure 2: Multiplate® Machine.	
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with internal Windows XP-based software; the operator, using the mouse 
and the keyboard, transmits the commands to test (Figure 2).   
In each of the five channels of the Multiplate®, a disposable cuvette is provided 
with two sensor units and a Teflon coated rotating magnet. The cuvette has a 
mouthpiece in which the blood and other reagents are inserted with the pipette and 
also has a cup portion in which the two pairs of electrodes long about 3.2 mm are 
embedded in silver coated. The electrodes protrude in the blood, and on the other 
hand, they connect to the instrument; so that it can be recorded the resistance 
between the two electrodes of each sensor unit. 
Once the cuvette has been inserted in one of the channels and connected to 
the instrument cable, we added 300 µl of a specific diluent solution for the agonist 
to be tested, followed by 300 µl of blood. After three minutes of incubation, 20 µl 
of the desired agonist is added. 
 
The most commonly agonist reagent used are (65):  
1- Thrombin receptor activating peptide-6 (TRAP-6), a thrombin analog that is 
actually a powerful platelet activator (TRAP test); 
Figure 3.  Multiplate® Cuvette.	
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2- Arachidonic acid, the substrate of cyclooxygenase which in turn forms as a potent 
platelet activator thromboxane A2 (ASPI test); 
3- Collagen, which binding to its receptor determines the release of arachidonic acid 
from which thromboxane A2 is produced (COL test); 
4- The ADP that stimulates ADP receptors on the platelet surface (ADP test); 
5- The ADP with the addition of 20 µl of prostaglandin E that in normal blood 
induces moderate platelet inhibition, while significantly increasing the sensitivity 
of the ADP test in patients treated with Clopidogrel (hence the name ADPHS test, 
high sensitivity) (66). 
The activated platelets adhere to the sensor wires; so, the electrical 
impedance between them increases Figure 4. 
 
 Figure 4. Multiplate® functional principle: The platelets adhere progressively to 
the electrodes resulting in an increase in the impedance. 
The increase in impedance in each pair of wires sensor is recorded by the 
machine, it is transformed into arbitrary aggregation units and placed in relation to 
time. Thus, two aggregation curves (AU)/time, one for each pair of electrodes are 
obtained. From each of these, three parameters are obtained: the aggregation, given 
by the maximum height of the curve; the speed given by the maximum slope of the 
curve; the area under the curve (Figure 5). 
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Figure 5. Representing chart obtained through the Multiplate® and their main 
values 
The area under the curve (AUC) is the most complete parameter obtained 
by Multiplate® because it is conditioned by both the maximum height of the curve 
and the slope, and therefore can be considered as the best indicator of total platelet 
activity. The area under the curve can be expressed in AU/min or in U where 1U 
corresponds to 10 AU/min. The analysis is believed to be reliable if the Pearson 
correlation coefficient between the values of the two curves is less than 0.98 and if 
the difference between the AUC of each curve and the mean of AUC between the 
two curves is less than 10%. 
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3-2 Multiplate® clinical application. 
The Multiplate® is applied as a Point-of-Care (POC) method as it’s easy to 
use and rapid information are obtained. In particular, when we have lower AUC 
values in the absence of surgical bleeding may indicate a reduction in platelet 
aggregation, whether it is due to reduced platelet count or impaired platelet function 
(67, 68). In addition, in presence of normal values of Multiplate® can also avoid 
platelet transfusions, even with low platelet counts, as demonstrated by a study 
conducted by Rahe-Mayer during and after cardiac surgery (69). Another important 
use of Multiplate® is the ability to differentiate the effects of various 
antiaggregation agents by analyzing the various activation pathways (65). Dual 
antiplatelet therapy (DAPT) with Aspirin and ADP receptor antagonists represents 
the standard treatment of patients with ACS and patients undergoing angioplasty 
with stent implantation. Drug metabolism alterations, interactions with other drugs, 
or other factors may diminish the response to DAPT. Therefore, the Multiplate® is 
a useful method in monitoring and controlling the effectiveness of therapy. Aspirin 
resistance is higher in patients with ACS, particularly in those with STEMI (70). 
The main mechanisms of that have been reported to be: a) reduced bioavailability 
of aspirin and/or interference with other drugs (eg NSAIDs such as ibuprofen which 
can prevent the bond of aspirin to serine 530); b) accelerated platelet turnover; c) 
TXA2 production from COX2 in newformed platelets or other cells; d) lack of 
compliance, that is probably the most common cause (71). 
Coronary angioplasty revascularization interventions could also induce 
temporary aspirin resistance. Zimmerman and others, in fact, demonstrated that 
inhibition of TxA2 biosynthesis by aspirin is compromised by a few days after PCI 
procedure. Although there was a 16-fold increase in platelet COX2, this would not 
be considered as the cause because specific COX-2 inhibitors do not lead to a 
reduction in resistance. On the other hand, Kearney and co-workers showed that 
coronary angioplasty is associated with an increase in TxA2 formation, but it would 
be completely inhibited by aspirin (72). Also, patients with Clopidogrel therapy had 
a variable response because of reduced bioavailability for a variable G protein-
mediated intestinal absorption, interference with other drugs such as 
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benzodiazepines and selective serotonin inhibitors (73). However, the main 
mechanism involved is reported to be the existence of polymorphisms of 
cytochrome P450, particularly of CYP3A4 and 3A5 isoforms (74, 75). 
In patients underwent percutaneous coronary angioplasty and treated with 
ADP receptor antagonists, ADP test values > 46 U indicate a high thrombotic risk 
as demonstrated by a study conducted by Sibbing and collaborators (76). In another 
study conducted by the same group, on patients with the same characteristics, it was 
observed that ADP test values <19 are indicative of high hemorrhagic risk (123). A 
study on aspirin-based patients showed that ASPI test values <40 U indicate 
inhibition of cyclooxygenase 1 (COX-1) by aspirin (77) and ASPI test values <30 
U indicate a strong inhibition of COX -1 (78). 
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4- Clinical impact and variability of response of antiplatelet agents therapy in 
acute coronary syndrome 
Rupture or erosion of an atherosclerotic plaque is by far the most common 
precipitating event of arterial thrombosis, accounting for approximately 75% of 
coronary thrombi leading to acute STEMI or death (1-5). Exposure of the 
thrombogenic lipid-rich core following plaque rupture leads to platelet activation 
that subsequently adhere to the damaged walls of blood vessels (79). Platelet 
activation is a key process in pathological thrombosis through the activation of 
multiple pathways by the binding of several agonists, such as thromboxane A2 
(TxA2), adenosine diphosphate (ADP), and thrombin, to their receptors (Fig.1). 
Release of ADP and TxA2 promotes the recruitment of circulating platelets into the 
growing stable hemostatic plug. Thrombin-mediated cleavage of fibrinogen into 
fibrin further contributes to the formation of hemostatic plugs. ADP activates 
platelets by binding to specific receptors on the platelet (P2Y1 and P2Y12 receptors 
for ADP), whereas TxA2 activates platelets by binding to specific receptors on the 
platelet prostaglandin G2 and H2 (PGG2 and PGH2) for TxA2. These bindings 
result in reduced intracellular cyclic adenosine monophosphate levels and full 
activation of GPIIb/IIIa. Other factors, such as thrombin (most platelet agonist), 
epinephrine, PGE2, serotonin, and several chemokines, play a role in platelet 
activation, mainly potentiating platelet activation induced by other stimuli (Fig. 1) 
(79-83). Consequently, the perpetuation phase of thrombus formation is mediated 
by the cell to cell contact-dependent mechanisms that lead to change platelet 
morphology, expression of pro-coagulant and pro-inflammatory molecules, and 
platelet aggregation (79-83). 
As the activation of multiple platelet pathways, in particular ADP and TxA2 
platelet activation pathways, is the primary mechanism of thrombosis and ischemic 
events, their comprehensive inhibition has represented an attractive therapeutic 
approach for the treatment of athero-thrombotic diseases (Fig. 1). On the other 
hand, the potential clinical benefits of targeting various platelet activation pathways 
should be weighed against the likelihood of increased bleeding (80). 
In the past few decades, oral antiplatelet agents that inhibit platelet 
activation by targeting cyclooxygenase 1 (COX-1) [acetyl salicylic acid (ASA) or 
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Aspirin] or ADP-induced P2Y12 receptor pathway [thienopyridines, such as 
Clopidogrel, Ticlopidine and more recently Prasugrel, and Ticagrelor] have proved 
to significantly reduce the incidence of ischemic events in patients with 
atherothrombotic diseases and widely used in the clinical practice (80, 82, 84). 
While single antiplatelet agent with aspirin is crucial in management of chronic 
atherosclerotic disease, a dual antiplatelet therapy is highly needed in the presence 
of acute platelets and clotting activation, as in conditions like ACS unstable angina 
and myocardial infarction (MI) (80, 85). 
The addition of Clopidogrel to Aspirin treatment had been demonstrated to 
reduce ischemic events in patients with cardiovascular disease. In the CURE trial, 
patients with non-ST-segment elevation ACS treated with Clopidogrel had a 20% 
relative risk reduction in the primary end point of cardiovascular death, MI or stroke 
at the expense of increased nonfatal major and minor bleeding (80, 86, 87). Current 
guidelines indicate Prasugrel or Ticagrelor as the first line-therapy, followed by 
Clopidogrel (88). These recommendations were derived from the results of the 
TRITON-TIMI 38 (89) and PLATO (90) trials, which have demonstrated a 
superiority of Prasugrel and Ticagrelor to Clopidogrel in terms of efficacy in 
reducing ischemic events (for Ticagrelor, a reduction was also was found in 
mortality) at the cost of a significantly higher proportion of bleeding events. These 
results fit in the situation of the high interindividual variability of Clopidogrel 
response. Recently, based on studies of Clopidogrel, it was demonstrated that the 
entity of platelet inhibition on Clopidogrel is a determinant of ischemic and, 
possibly, bleeding events during the follow-up in patients with ACS (91-93).  
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4-1 High on-treatment platelet reactivity (HPR). 
Notwithstanding the dual antiplatelet therapy is the current standard of care 
for ACS patients and patients undergoing stent implantation, recurrent ischemic 
events often occur during dual-antiplatelet therapy (94). Up to 25% of patients with 
acute MI undergoing PCI were found to have variable response to Clopidogrel, 
predisposing them to recurrent events of ACS (95). However, Gori et al. reported 
that the incidence of dual nonresponsiveness to Aspirin and Clopidogrel is a 
relatively infrequent (about 6%) condition and the incidence definite/probable drug-
eluting stent thrombosis was significantly higher in dual Aspirin and Clopidogrel 
nonresponders than in Clopidogrel and Aspirin responders, isolated Clopidogrel 
nonresponders, or Aspirin nonresponders (96). The possibility to study platelet 
function, formerly with complex laboratory techniques (e.g. light transmission 
aggregometry) and more recently with Point-of-Care devices (e.g. multiple 
electrode aggregometry) has made it possible to identify patients with high platelet 
reactivity while taking one or multiple antiplatelet drugs (97). In particular, high 
on-aspirin platelet reactivity (HaPR) and high on-clopidogrel platelet reactivity 
(HcPR) have been associated with a higher risk for major cardiovascular events in 
patients with ACS (91, 98-100) (Figure 6). However, whole blood platelet function 
tests are influenced by several pre-analytical variables (e.g. platelet count, 
haematocrit, method and site of sample collection, temperature, anticoagulant used, 
etc.) leading to a lack of standardization and ultimately to clinical misinterpretation 
(101). There are conflicting evidences in current literature with respect to the 
influence of the site of sample collection on platelet function (102-106).  
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Figure 6.  Platelet test function and risk of adverse outcome after PCI.  BNP: 
brain natriuretic peptide; CRP: C-reactive protein; DAPT: dual antiplatelet therapy; HPR: high on-
treatment platelet reactivity; HPPR: high on-P2Y12 inhibitor platelet reactivity; PCI: percutaneous 
coronary intervention. 
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4-1-1 High on-aspirin reactivity (HaPR):  
It has been demonstrated the role of Aspirin reactivity by the ISAR-ASPI 
registry (94) in which PCI treated patients with HaPR showed a significantly higher 
risk of death or stent thrombosis at 1 year. HaPR, measured at the time point of the 
PCI, was associated with a higher risk for death or stent thrombosis during the first 
year after PCI. It has been established that diabetic patients with ACS associated 
with significant higher risk of HaPR and recurrent events than nondiabetic ACS 
patients (80, 107).  
In spite of sharp declines in restenosis rates with the use of drug-eluting 
stents (DES), diabetic patients with ACSs remain at the highest risk for recurrent 
ischemia (80, 108). Recently, multiple studies have suggested that diabetes is an 
independent predictor of stent thrombosis and lower survival rates in patients 
treated with DES (80, 109, 110). It has been proposed that diabetic patients not 
treated with aspirin therapy generally display HaPR and elevated levels of platelet 
thromboxane synthesis, and on other hand, in diabetic patients, Aspirin is less 
effective in inhibiting thromboxane synthesis than in nondiabetic patients (80, 111). 
In the ASPECT randomized study, it was shown that, diabetic patients had a higher 
platelet function and consequently Aspirin resistance than nondiabetic patients. In 
general, increasing the dose of Aspirin in the diabetic patient to reduced platelet 
function and thus the prevalence of Aspirin resistance to levels observed in the 
nondiabetic patient, suggests that low-dose aspirin therapy may not provide 
adequate platelet inhibition in selected diabetic patients and that higher Aspirin 
dosing reduces the prevalence of aspirin resistant patients (80, 112). A systematic 
review combined data from multiple studies to examine the relationship between 
daily aspirin dose and prevalence of HaPR showed diabetic patients were 36% more 
likely to have HaPR compared with nondiabetic ones (80, 113). 
Among the possible mechanisms underlying HaPR in diabetes, it was 
hypothesized that faster recovery of platelet COX-1 activity may explain 
incomplete thromboxane inhibition during the 24-hour dosing interval. In another 
study with an Aspirin 100 mg twice daily completely reversed the abnormal TxB2 
recovery in diabetic patients suggesting that interindividual variability in the 
recovery of platelet cyclooxygenase activity during the dosing interval may limit 
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the duration of the antiplatelet effect of low-dose Aspirin in patients with and 
without diabetes (80, 114). Others possible causes of high on Aspirin platelet 
reactivity are listed in figure 7. 
 
       Figure 7. The possible causes of aspirin failure response. 
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4-1-2 High on–clopidogrel platelet reactivity (HcPR). 
Clopidogrel has a peculiar metabolism which has been ameliorated by the 
other new antiplatelet agents. First of all, the hepatic conversion by cytochrome 
P450 is required. Studies measuring platelet function in patients administered 
Clopidogrel showed that this treatment is associated with an overall variable 
response and modest level of P2Y12 inhibition even when high loading doses are 
used (80, 115-117) In addition to distinct response variability, a considerable 
percentage of patients will also exhibit complete non-responsiveness to Clopidogrel 
(80). However, genetic play important role in the phenomenon HcPR, which is 
associated with a number of other clinical and laboratory parameters, in addition to 
the possible interaction with other drugs. Different CYP450 isoenzymes involved 
in Clopidogrel metabolism have been associated with inactivation of the enzyme 
and impaired metabolism of Clopidogrel. CYP2C19*2 genetic polymorphism, 
however, does not fully explain the association between HcPR and adverse events 
observed in patients taking Clopidogrel: even within a population which is not 
carrying the CYP2C19*2 polymorphism, which is consequently able to metabolize 
Clopidogrel, the extent of ADP-induced inhibition of platelet function remains a 
marker of risk of adverse events (80, 118). The failure in Clopidogrel response may 
be due to others chronic conditions, such as, inadequate drug compliance, drug–
drug interactions, age, diabetes mellitus, elevated body mass index (BMI), female 
sex and reduced left ventricular ejection fraction (LVEF). All these mechanisms 
could interact with the genetic predisposition in determining inadequate response 
to Clopidogrel and consequently the increased risk of occurrence of major adverse 
cardiovascular events (MACE), including stent thrombosis. A particularly 
important aspect of the possible existence of acquired determinants of HcPR is the 
role of ‘acute phase’: it was shown how inflammation and increased platelet 
turnover that characterize the acute phase of ACS are associated with increased 
platelet reactivity and with a higher risk of HcPR during treatment (119). Others 
transient mechanisms include inflammation, accelerated platelet turnover, 
reticulated platelets (RPs), erythrocyte deformability, and the activity of 
ADAMTS13 (80, 120). Certainly, re-evaluating the patients away from the early 
phase of an acute inflammation event, the percentage of subjects with HcPR 
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decreases significantly, suggesting that, when the inflammation related to the acute 
phase is extinguished, the degree of platelet reactivity, and therefore the percentage 
of patients with an inadequate inhibition, are also significantly reduced (80). 
Moreover, Martin et al. noted that platelets of patients with ACS had an increased 
mean volume, probably due to the presence of RPs, newly formed platelets with a 
higher granule content. An increased plasma level of RPs is also claimed to be 
independent predictor of recurrent MI and cardiac death (121). Definitely, it has 
been demonstrated that a more significantly elevated percentage of RPs is present 
in patients with HcPR compared to those without suggesting that the presence of 
these immature and more active platelets could be another mechanism involved in 
the variable response to antiplatelet therapy (119). Others possible causes of high 
on Clopidogrel platelet reactivity are shown in figure 8. 
 
 
    Figure 8. The possible causes of Clopidogrel failure response. 
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4-2 Low on-treatment platelet reactivity (LPR):  
In the clinical setting of dual antiplatelet therapy in ACS, bleeding was often 
considered as an expectable complication. Both TRITON TIMI-38 (89) and 
PLATO (90) demonstrated a superiority in the reduction of ischemic events of 
Prasugrel and Ticagrelor on Clopidogrel, but both with a significant higher bleeding 
risk. The balance between the absolute risk reduction in ischemic events and the 
absolute risk increase in bleeding events with more potent agents remains to be well 
defined. The focus is now shifting toward finding strategies that could avoid 
excessive bleeding while maintaining the benefit of reduced ischemic/thrombotic 
events. Furthermore, bleeding events have been associated with an increased risk 
of short-term and long-term morbidity and mortality in cardiovascular patients 
during long-term antiplatelet and anticoagulant therapy (80, 122). Observational 
studies involving patients undergoing PCI have suggested a possible link between 
LPR and bleeding (80, 123-128). Parodi et al. reported that patients undergoing PCI 
with LPR on Prasugrel therapy had more frequent access site bleeding (129). A 
recent collaborative analysis on 17 studies, patients with LPR showed a 1.7-fold 
higher risk for major bleeding complications without any further reduction in the 
risk of stent thrombosis compared to patients with optimal platelet reactivity (80, 
130). Hypothesized preliminary concept of therapeutic window of platelet 
reactivity on dual antiplatelet therapy, that similar to the international normalized 
ratio (INR) range used for warfarin therapy, is shown in figure 9 (97). 
Figure 9. On-treatment platelet reactivity and therapeutic window concept. PRI: 
platelet reactivity index, PRU: P2Y12 reaction units, U: unite and VASP: vasodilator-stimulated 
phosphoprotein 
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4- AIM OF THE STUDY 
The aim of our study was to assess the on-treatment platelet reactivity in 
peripheral and coronary arterial blood, in a group of patients receiving dual 
antiplatelet therapy following primary percutaneous coronary intervention (p-PCI) 
for STEMI. 
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5- MATERIAL AND METHODS 
5-1 Study design 
This is a cohort observational study based on prospective registry of patients 
undergoing primary percutaneous coronary intervention (p-PCI) for STEMI. 
 
     5-2 Patients eligibility 
All consecutive patients who underwent p-PCI for STEMI at the Cardiology 
Unit of Padua University Hospital between June 2014 and June 2015 were 
considered for enrollment.  
     5-2-1 Inclusion criteria 
Inclusion criteria were: continuous chest pain for at least 20 min within 12 
h from onset and (i) ST-segment elevation ≥1 mm (0.1 mV) in two or more 
contiguous leads on the 12-lead electrocardiogram or (ii) persistent ST-segment 
depression in precordial leads V1-V4, with or without ST-segment elevation in 
inferior or lateral leads or (iii) new onset left bundle branch block.  
     5-2-2 Exclusion criteria 
Exclusion criteria were: (i) patients who reperfused with thrombolytic 
therapy before PCI, (ii) contraindication for antiplatelet therapy, (iii) variant angina 
(iv) prior coronary bypass surgery, (v) severe renal dysfunction (creatinine 
clearance < 30 mL/min/1.73 m2), (vi) concomitant chronic inflammatory or 
malignant disease, (vi) pregnancy, (vii) thrombocytopenia (platelet count ≤100 
x109/L) and (viii) refusal to sign written informed consent.  
 
     5-3 Biochemical analysis and timing of blood sampling 
A group of 109 healthy volunteers age- (±3 years) and sex-matched with 
cases were selected as controls to establish reference values of the laboratory 
parameters measured in the study. Before the procedure, all patients, at emergency 
room or coronary care intensive unit, received: a) intravenous unfractionated 
heparin (starting dose 70 U/kg) to maintain an activated clotting time ≥ 250 s; b) 
intravenous aspirin 250 mg; c) oral Clopidogrel 300/600 mg, Prasugrel 60 mg or 
Ticagrelor 180 mg. 
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Primary percutaneous coronary intervention (P-PCI) was performed following the 
standard radial approach, or femoral approach in patients with unsuitable radial 
arteries. 
 
5-3-1 Preparation of blood samples  
Peripheral blood samples were collected from patients right before the p-
PCI procedure, using a 19-Gauge needle and 4 BD vacutainer tubes (Becton 
Dickinson, Franklin Lakes, New Jersey) containing sodium citrate 109 Mmol/l 
(3.8% sodium citrate) and 1 BD Vacutainer containing Ethylenediaminetetraacetic 
acid 5.4 mg (EDTA) were filled. Another blood sample was drawn from the 
coronary arterial catheter guide after cannulation of the infarct-related artery (IRA). 
Specifically, 2 BD Vacutainer tubes (Becton Dickinson, Franklin Lakes, New 
Jersey) containing sodium citrate 109 Mmol/l (3.8% sodium citrate) and 1 BD 
Vacutainer containing Ethylenediaminetetraacetic acid 5.4 mg (EDTA) were filled.  
Peripheral and coronary arterial blood samples from each patient were used, in 
accordance with standard procedures, to measure the following parameters: 
hemoglobin (Hb, gr/dl), hematocrit (Htc, %), platelet count (x109/L), activated 
partial thromboplastin time (aPTT, sec.), prothrombin time (PT, %), d-dimer 
(ug/L), fibrinogen (g/L) and antithrombin (AT, %).  
One-hundred samples of peripheral and coronary blood were collected, with the 
same measurement mentioned above, as control group from group of patients 
underwent coronary angiography for reasons other than ischemic heart disease.  
 
5-3-2 Point-of-Care platelet reactivity assays 
Both peripheral and coronary arterial blood samples were used to determine 
impedance aggregometry via the Multiplate electrode aggregometry (MEA, Roche 
Diagnostics SpA, Monza, Italy), in accordance with the manufacturer’s protocol. 
Specifically, aggregation in response to arachidonic acid (ASPI-test) and ADP 
(ADP-test) was tested within 30 minutes of blood collection. The apparatus was 
heated in order to maintain the measurement temperature above 36 °C.  We placed 
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300 µl of a diluent solution inside designated cuvettes and then added 300 µl of 
citrated blood from the patient at room temperature. The diluent solution was 
physiological saline (0.9% NaCl) at 37° C for the ASPI-test and NaCl-CaCl2 (0.9% 
NaCl with 3 mM CaCl2) at 37° C for the ADP test. Following a 3-minute 
incubation, we added 20 µl of 15 mM arachidonic for the ASPI-test and 20 µl of 
0.2 mM ADP for the ADP-test.  
After adding the reagent, the instrument automatically measures the change in 
electrical impedance between two sensor electrodes (e.g. aggregation curves, 
AU/time). Each cuvette contains two pairs of electrodes. The measurement ends 
after a standard time of 6 minutes. The parameter used to describe the curve was 
area under the curve (AUC) corresponding to the first derivative of the mean area 
under the curves measured by the two pairs of electrodes. The higher the AUC value 
the higher the capacity of platelets to aggregate, the lower the AUC value the lower 
the capacity of platelets to aggregate (131). “Low responders of antiplatelet 
therapy” were considered when an AUC value of ASPI-test or ADP-test greater 
than or equal to a pre-established normal range. The samples with a coefficient of 
variation greater than or equal to 10% between the two curves obtained in each 
cuvette were rejected and the test repeated. The control group samples underwent 
validation test with the same measurement mentioned above for both ASPI-test and 
ADP-test. 
 
5-4 Interventional procedure 
P-PCI were performed with standard technique by radial approach, or 
femoral approach in patients with unsuitable radial catheterization. After guide-
wire positioning in the distal IRA, one or more manual thrombus aspiration attempts 
were made by Export catheter. Thrombus aspiration were based on step-by-step 
technique, starting just proximally to culprit lesion, and advancing the aspiration 
catheter very slowly through the lesion, to avoid distal embolization of debris 
removed by catheter tip. Repetition of this maneuver was accomplished according 
to angiographic results obtained. In particular, if the thrombus was not 
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reduced/removed additional attempts were performed using the same technique. 
The IRA was the only target of the procedure, and deployment of coronary bare 
metal stents or drug-eluting stents was left at operator’s discretions. The procedure 
was considered successful if Thrombolysis In Myocardial Infarction (TIMI) 3 in 
the target vessel and a residual stenosis ≤ 20% at target site were obtained. Before 
the procedure, all patients, at emergency room or coronary care intensive unite, 
received: a) intravenous unfractionated heparin (starting dose 70 U/kg) to maintain 
an activated clotting time ≥ 250s; b) intravenous Aspirin 250 mg; c) oral 
Clopidogrel 300/600 mg, Prasugrel 60 mg or Ticagrelor 180 mg. All patients had 
been given written informed consent to the procedure. 
 
5-5 Angiographic analysis 
 Coronary angiograms were acquired by using digital technique (Integris 
5000, Philips Medical Systems, Best, The Netherlands). In order to better define 
the thrombus burden in case of IRA occlusion, the angiographic pattern of coronary 
occlusion, when present, was defined on baseline angiogram as follows: (i) cut-off 
pattern, when there was an abrupt occlusion of the epicardial vessel; (ii) tapered 
occlusion, when there was a vessel tapering just before the occlusion; (iii) persistent 
dye pattern, when there was a dye staining just proximally and/or distally to the 
occlusion (28). Intracoronary thrombus well is angiographically identified and 
scored in 5 grades as previously described (132). According to this classification, 
in thrombus grade 0 (G0), no cineangiographic characteristics of thrombus were 
present; in thrombus grade 1 (G1), possible thrombus were present, with such 
angiography characteristics as reduced contrast density, haziness, irregular lesion 
contour, or a smooth convex meniscus at the site of total occlusion suggestive but 
not diagnostic of thrombus; in thrombus grade 2 (G2), there were definite thrombus, 
with greatest dimensions ≤ 1/2 the vessel diameter; in thrombus grade 3 (G3), there 
were definite thrombus but with greatest linear dimension > 1/2 but <2 vessel 
diameters; in  thrombus grade 4 (G4), there were definite thrombus, with the largest 
dimension ≥ 2 vessel diameters; and in thrombus grade 5 (G5), there was total 
occlusion (unable to assess thrombus burden due to total vessel occlusion). 
Subsequent PCI was performed for total occlusive lesions or lesions with >75% 
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diameter stenosis (DS), even with TIMI grade 3 flow. Thromboaspiration was 
performed whenever possible (when the anatomy of the coronary artery-curve and 
size-allowed it) in all patients with a Thrombolysis In Myocardial Infarction (TIMI) 
flow grade 0 and in all patients with a visible thrombus if TIMI flow grade was 1 
or more. 
Thrombosis In Myocardial Infarction (TIMI) flow and myocardial blush were 
assessed as previously reported (133). Distal embolization (DE) was defined as a 
distal filling defect with an abrupt ‘cut-off’ in one or more peripheral coronary 
branches of IRA, distal to the PCI site; in particular, we would not consider as DE 
the occurrence of TIMI flow impairment, at any stage of the procedure, without 
evidence of distal filling defect (28, 134). Angiographic no-reflow was defined as 
substantial coronary antegrade flow reduction (less than Thrombolysis in 
Myocardial Infarction [TIMI] flow grade 3) without mechanical obstruction (135). 
All angiographic and procedural parameters, including thrombus classification, 
were assessed by 2 experienced interventional cardiologists reviewing the 
angiograms together, who were unaware of the patients’ characteristics. Both 
reviewers were blinded to clinical outcomes. Consensus were achieved in all 
patients. Half of the films were randomly selected and reanalysis by the same 
analysts for intraobserver variability, and by a third experienced interventional 
cardiologist for interobserver variability of the proposed large thrombus burden 
lesion (LTBL) and small thrombus burden lesion (STBL) classification. 
Quantitative coronary analysis was performed at baseline and after procedure, using 
the Coronary Quantification Package (Philips Medical Systems): minimal lumen 
diameter, reference vessel diameter, percent of stenosis in diameter will have 
provided; lesion length will also be assessed at baseline angiography, or after vessel 
reopening (by either wire positioning or balloon pre-dilatation) in patients with 
occluded IRA at baseline.  
 
5-6 Electrocardiographic analysis  
In each patient, a 12-lead electrocardiogram was recorded at admission and 
60 + 30 min after the procedure. The sum of ST-segment elevation was assessed at 
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20 ms from J-point in the leads V1 – V6, I, and aVL for anterior infarction and in 
the leads II, III, aVF, V5, and V6 for non-anterior infarction; in the latter, the ST-
segment depression in leads V1 – V4 was also analyzed, as a sign of transmural 
ischemia of the posterior wall. The two electrocardiograms were compared and the 
ST-segment elevation was classified as normalized if there was no residual ST-
segment elevation after the procedure, improved if a regression ≥ 50% was seen 
and unchanged if the ST-segment elevation sum appeared unchanged, worsened, or 
regressed ≤50% (136). 
 
5-7 Measures of outcome  
 Major adverse events occurring during the hospitalization, including death, 
non-fatal re-infarction, heart failure and stroke, stent thrombosis, bleeding and need 
to urgent intervention were collected. Diagnosis of non-fatal re-infarction bases on 
typical chest pain and/or new ST-segment changes with Troponin I level re-
elevation (28, 137). The Troponin I levels were reported as micrograms per liter, 
and assessed every 6 hours during the first 48 after admission, and then twice daily 
up to discharge (28, 137). Peak value release from eight serial measurements up to 
48 hours after admission was reported (28, 137). Stroke defined as development of 
new cognitive or neurological deficit confirmed by computed tomography or 
magnetic resonance imaging (28, 137). All patients underwent 2D-transthoracic 
echocardiographic examination before discharge.  
 
 
5-8 Clinical follow-up   
All patients were discharged on aspirin (100 mg) indefinitely and 
Clopidogrel 75 mg once a daily, Prasugrel 10 mg once a day or Ticagrelor 90 mg 
twice a day for 6–12 months. The follow-up protocol included an evaluation at 
hospital discharge and at 12-month follow-ups. The 1-year clinical outcomes 
included all-cause death, MI, target vessel revascularization, stent thrombosis and 
bleeding. Major adverse cardiac events (MACE) were a composite of all-cause 
death, MI, and TVR during a 1-year follow-up. 
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5-9 Statistical methods  
Statistical analysis was performed using the PASW Statistics 17.0.2 (SPSS Inc.) 
for Windows. Continuous variables were expressed as mean ± standard deviation 
(SD). Differences between frequency distribution according to qualitative variables 
were calculated using Chi-square test. The parametric t-Student test or the non-
parametric Mann–Whitney U was used to test for differences between variables, 
where appropriate. For multiple comparisons (differences between three groups), 
the Kruskall-Wallis test was used. Spearman’s correlation was used to detect 
significant associations between variables. For the clinical outcomes during the 
follow-up a descriptive statistical analysis was used (i.e. prevalence, percentage and 
chi-square test). Upper and lower limits of reference range in contolswere 
calculated as mean+2SD and mean-2SD. P value <0.05 was considered statistically 
significant.	
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6- RESULTS 
During the study period one hundred eighteen patients were considered for 
enrollment. Four patients were excluded because they did not receive 
thienopyridines before the procedure, three refused to give their informed consent 
and two had severe renal insufficiency. Eventually, 109 patients (age 64±13 years, 
Male/Female 79/30) were enrolled. On the issue of cardiovascular risk factors, 56 
(51%) patients were active smokers, 71 (65%) suffered from hypertension, 60 
(55%) with dyslipidemia and 26 (24%) with diabetes. The main baseline 
characteristics of the studied population are summarized in the Table 2.  
The elapsed time (mean ± SD) between the administration of aspirin and 
thienopyridines and the start of procedure was 81±63 min and 61±53 min, 
respectively. 
	
Table 2: Main baseline characteristics.  
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6-1 ASPI-test and ADP-test 
In ASPI-test, normal AUC values were considered between 35U and 87U. 
On peripheral blood, the mean values were 23 ± 4 U, however below the normal 
range, as well as at the coronary level, where the mean values were even lower (17 
± 2 U). Comparison between the two medians by student T test showed no 
statistically significant difference between mean values for peripheral and coronary 
blood, with a p-value equal to 0.06 (Table 3, Figure 10 a). 
 In ADP-test, normal AUC values range between 39U and 79U. On 
peripheral blood test, the mean values were 41 ± 28 U, i.e. a value within the normal 
range. The same was observed in the ADP-test performed for coronary blood, 
where, however, the mean values were lower (39 ± 28 U), however within the 
normal range. In particular, the comparison between the two averages through 
student's T test showed that the difference between the two means was not 
statistically significant, with a p-value =0.68 (Table 3, Figure 10 b). 
Thus, no statistically significant differences were observed in ASPI-test 
between peripheral (23±4 U) vs coronary (17±2 U, p=0.06) blood and in ADP-test 
between peripheral (41±28 U) vs coronary (39±28 U, p=0.68) blood. 
	
Table 3: Mean and Median AUC values obtained in ASPI-test and in ADP-test 
by Multiplate® methods. Median (10-90 Percentiles) 
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Figure 10: Distribution of mean AUC in peripheral and coronary blood: a) 
ASPI-test and b) ADP-test. The horizontal line inside the box represents the median AUC 
levels. Grey area refers to normal range.   
These data show that the overall platelet reactivity in coronary blood is lower than 
in peripheral blood, though without statistical significance, it more likely appears 
due to highly DAPT effect at atherosclerotic plaque ulceration/thrombus formation 
site where the hemostatic process is highly active at onset of STEMI. 
In consideration of normal mean AUC values of ASPI-test observed in 
healthy subject control were (61±13 U), with an  observed statistically significant 
difference in ASPI-test between patients (either in peripheral and in coronary blood) 
and controls (Figure 11). Similarly, in ADP-test, being the normal AUC values 
(59±10 U), we observed a significant difference in ADP-test between patients 
(either in peripheral and in coronary blood) and healthy individual controls (Figure 
11). 
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Figure 11: ASPI-test and ADP-test in diseased patient blood (peripheral and 
coronary) in comparison with control group.  
Further data emerged from the study, we found statistically significant linear 
correlation between low responders to acetylsalicylic acid (evaluated by ASPI-test) 
and low responders to ADP receptor inhibitors (assessed by ADP-test) (Figure 12). 
That means, patients with an AUC value in ASPI test within or above the normal 
range tend to have an AUC value in ADP-test either within or above the range in 
the same sample of blood; as well, patients with AUC below the normal ASPI-test 
values tend to have values below the range in ADP-test in same sample of blood. 
	
Figure 12: Linear correlation relationship between ASPI-test values and ADP-
test values in peripheral blood and coronary blood. C= Coronary blood; r2= 
Coefficient of correlation; P=peripheral blood.  
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In summery; a positive and statistically significant linear correlation was observed 
for both ASPI-test and ADP-test in peripheral and coronary blood (r2 0.23, p <0.001 
and r2 0.12, p <0.001; respectively) (Figure 12). 
No statistically significant correlations were observed with respect to age, 
hematocrit, antithrombin, PT, aPTT, fibrinogen and D-Dimer plasma levels for 
either ASPI-test or ADP-test in peripheral and coronary blood except for platelet 
count (Table 4). In both peripheral and in coronary blood, no significant correlation 
was observed in regard to the elapsed time between the administration of aspirin 
and the ASPI-test, and between the administration of thienopyridines and the ADP-
test (Table 4) 
 
Table 4: Comparison of classic coagulation parameters & elapsed time 
between the administration of antiplatelet drugs and ASPI/ADP tests. 
APPT= activated partial thromboplastin, AT= antithrombi, PT= prothrombin time, r= coefficiente 
of correlation. 
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In a subgroup analysis of 15 patients <50 years (range 34-49), we observed 
no significant difference neither in peripheral nor in coronary blood between this 
subgroup of patients and the overall study population in regard to ASPI-test and 
ADP-test results or low responders to antiplatelet therapy (Table 5). 
 
Table 5: Subanalysis according the age of population. 
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6-2 Low Aspirin/Thienopyridines responders 
In our study, the values of AUC of ASPI-test and ADP-test (mean ± SD) in 
the group of controls were 61±13 U and 59±10 U, respectively. Having established 
cut-off values of 35 U for ASPI-test and 39 U for ADP-test, corresponding to the 
respective lower limits of the normal range measured in controls (from 35 U to 87 
U for ASPI-test and from 39 U to 79 U for ADP-test). We observed, in peripheral 
blood 15 (14%) patients with an ASPI-test value (e.g. “low aspirin responders”) and 
41 (38%) patients with an ADP-test value (e.g. “low thienopyridines responders”) 
above their respective cut-offs (Table 6). In the coronary blood, we observed 12 
(11%) patients with an ASPI-test value and 39 (36%) patients with an ADP-test 
value above their respective cut-off (Table 6). 
	
Table 6: Mean values of ASPI-test/ADP-tests and the prevalence of “low 
aspirin/thienopyridines responders” in the study population. SD, standard 
Deviation. 
No significant difference (p >0.05 in all comparisons) between this group of 
patients with both ASPI-test and ADP-test results above the predefined cut-offs and 
the overall study population with respect to age (63±14 vs 65±13 years), sex 
(Male/Female 9/3 vs 70/27; respectively), platelet count (229±175 vs 272±130 
x109/L), fibrinogen (3.7±1.3 vs 3.9±1.10mg/dl) and elapsed time between drugs 
administration and aggregometry evaluation (ASPI-test 82±65 vs 69±42 min; ADP-
test 63±55 vs 42±36 min) (Table 7). Moreover, there was no significant difference 
on the prevalence of smoking (67 vs 51%), hypertension (67 vs 66%), 
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hypercholesterolemia (75 vs 53%) and diabetes (25 vs 24%) in subjects with both 
ASPI-test and ADP-test results above the predefined cut-offs compared with the 
study population (p >0.05 in all comparisons) (Table 7).   
	
Table 7: Comparison of low responders to antiplatelet therapy observed in 
ADP-test and ASPI-testing according to baseline characteristics of study 
population. 
By definition, patients who are taking antiplatelet drugs and have mean 
AUC values within or above the normal range are considered to be low responders 
to antiplatelet therapy. Regarding the ADP-test, where the normal AUC values 
between 39U and 79U, it was observed that in peripheral blood, 38% patients did 
not respond as expected to ADP inhibitor therapy. At a coronary level, patients who 
had AUC values greater than 39U at the ADP-test were 36%. By comparing 
percentages through the chi-square test, it was found that the difference in low 
responder to ADP inhibitors in peripheral and coronary blood was not statistically 
significant (Figure 13). 
In relation to the ASPI test, normal AUC values are between 35U and 87U. 
In peripheral blood analysis, 14% patients were found to be low responders to 
acetylsalicylic acid treatment. On coronary blood, the number of low responders to 
treatment was 11%. Applying the chi-square test for the comparison of percentages, 
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there was no statistically significant difference between the percent of low 
responders to acetylsalicylic acid between peripheral and coronary blood (Figure 
13). 
Finally, we directly compared the mean values obtained in ADP-test and 
ASPI-test initially in the peripheral blood then in coronary blood, based on the fact 
that the normal range for both tests is approximately similar (39-79 U and 35-87 U, 
respectively) and we observed a statistically significant difference between low 
responders to ADP receptor inhibitors (evaluated with ADP-test) and low 
responders to acetylsalicylic acid therapy (evaluated with ASPI–test) in both 
peripheral blood and coronary blood. In particular, it was found that the prevalence 
of low responders to thienopyridine was significantly greater than to acetylsalicylic 
acid, both in peripheral blood and in coronary blood, with a p-value less than 0.01 
(Figure 13). Twelve (11%) in peripheral blood and ten (9%) patients in coronary 
blood had both ASPI-test and ADP-test results above the cut off values. 
 
Figure 13: Percentage of low responders to antiplatelet therapy assessed by 
ADP-test and ASPI-test in both peripheral and coronary blood. 
The aggregometry Multiplate® results showed responsiveness failure to antiplatelet 
treatment with P2Y12 inhibitors, in at least one third of cases, at time of p-PCI.  
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We found statistically significant linear correlation between low responders 
to acetylsalicylic acid (evaluated by ASPI-test) in coronary blood and low 
responders to the same test in peripheral blood. Likewise, for low responders to 
ADP receptor inhibitors (assessed by ADP-test) in coronary blood had significant 
linear correlation relationship to the same test in peripheral blood. That means; 
interestingly enough almost all patients with a coronary ASPI-test value above the 
cut-off also had a peripheral value of the same test above the cut-off as well as for 
ADP-test (Figure 14). This significant direct correlation between platelet reactivity 
in peripheral and in coronary blood is still a matter of debate.  
	
Figure 14: Linear correlation between ASPI-test and ADP-test in peripheral 
vs coronary blood. 
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6-3 Clopidogrel, Prasugrel and Ticagrelor 
 
Before the PCI procedure, antiplatelet therapy was performed in all cases 
with the use of Aspirin 250mg I.V in combination with one of the following ADP 
receptor inhibitors: Clopidogrel 300/600 mg, Prasugrel 60 mg or Ticagrelor 180 
mg. The prevalence of thienopyridines was distributed as follow: Clopidogrel n 22 
(20%), Prasugrel n 69 (63%) and Ticagrelor n 18 (17%) (Figure 15).  
 
 
 
Figure 15: Choice of ADP receptor inhibitor in dual antiplatelet therapy. 
 
 
 
 
 
 
 
 
 
 
		
	
53	
The main baseline characteristics of the studied population regarding the use 
of ADP receptor inhibitors (Clopidogrel, Prasugrel and Ticagrelor group) are 
summarized in the Table 8. 
 
	
Table 8: Main baseline characteristics of population according to 
thienopyridine drugs. M: male, F: Female 
The study attempted to identify a relationship between “low responders to 
antiplatelet therapy” and the type of drug used. In particular, mean values of AUC 
in ADP test were compared among the three groups of patients, according to the 
thienopyridine used. In peripheral blood, ADP-test results were 47±31 U in patients 
taking Clopidogrel, 39±27 U in patients taking Prasugrel and 39±28 U in those 
taking Ticagrelor (Table 6). In coronary blood, ADP-test results were 44±33 U in 
patients taking Clopidogrel, 39±28 U in patients taking Prasugrel and 37±32 U in 
those taking Ticagrelor (Table 6). Irrespective to the thienopyridine administered, 
no statistically significant difference was found comparing ADP-test results in 
peripheral vs coronary blood (Figure 16). Regarding peripheral blood among 
patients taking Clopidogrel 10 (45%) had ADP-test values above the predefined 
cut-off; a lower prevalence of “low responders” was observed among patients 
taking Prasugrel 25 (36%) and Ticagrelor 6 (33%) (Table 6).  
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No significant difference (p =0.69) was observed on the prevalence of 
patients with ADP-test values above the cut-off considering the three different 
thienopyridines separately. As for coronary blood, 9 (40%) taking Clopidogrel, 25 
(36%) patients taking Prasugrel and 5 (29%) patients taking Ticagrelor had ADP-
test values above the predefined cut-off (Table 6). However, these findings were 
not statistically significant (p >0.05). That means, the antiplatelet therapy during a 
STEMI seems to be equally effective in inhibiting platelet function both in 
peripheral and in coronary blood. 
	
Figure 16. ADP-test results in peripheral and coronary blood in relation to 
Clopidogrel, Prasugrel and Ticagrelor treatment. In each box plot, the lower and 
upper bars represent the 10th and 90th percentiles, respectively; the lower and upper ends of the box 
represent the 25th and 75th percentiles, respectively; and the horizontal line inside the box represents 
the median AUC levels 
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6-4 Clinical outcome.  
Three cardiovascular deaths (2.8%) occurred during hospitalization, two of 
which due to cardiogenic shock and one due to cardiac rupture. Cardiogenic shock 
occurred in 8 patients (7.3%) whereas two cases (1.8%) had congestive heart 
failure. Myocardial re-infarction needing to urgent re-intervention occurred in 3 
cases (2.8%); one of them underwent coronary artery by-pass grafting and two cases 
underwent re-PCI. There were three cases (2.8%) of sub-acute stent thrombosis and 
two patients (1.8%) had a non-fatal ischemic stroke. Five patients had major 
bleeding that needed urgent blood transfusion. The overall incidence of in-hospital 
major bleeding events in these patients was 4.6%. Five patients (4.6%) had 
combined major adverse cardiovascular events (death, non-fatal MI and target 
vessel revascularization) (Table 9). 
	
Table 9. In-hospital outcome. CHF= Congestive heart failure; MACE= Major adverse 
cardiovascular events; Re-MI= Re-myocardial infarction; TVR= Target vessel revascularization. 
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Out-of-hospital clinical outcomes at 12 months (Table 10)  
Clinical follow-up at 12 months was completed in all of patients. After 
discharge, there was one cardiovascular death (0.9%). Non-fatal MI occurred in two 
patients (1.8%) whereas angina/NSTEMI happened in six patients (5.5%). Out of 
them, 3 patients (2.8%) underwent target vessel revascularization. Atypical non 
cardiac chest pain with evaluated in emergency room occurred in 5 cases (4.6%). 
None of these patients had late stent thrombosis nor major or minor bleeding. All 
other events like congestive heart failure, tachyarrhythmia and hypertensive crisis 
had occurred in about 2% of cases and needed re-hospitalization. As a total six 
patients (5.5%) had combined major adverse cardiovascular events (death, non-fatal 
MI and target vessel revascularization). 
	
Table 10. Out-of-hospital clinical outcomes. CHF= Congestive heart failure; MACE= 
Major adverse cardiovascular events; MI= Myocardial infarction; TVR= Target vessel 
revascularization. 
Our data showed no correlation between platelet reactivity function and clinical 
outcome neither for in-hospital outcome nor for clinical outcomes at 1-year, most 
probably due to the small size of the population of the study. 
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7- DISCUSSION 
The increasing, and sometimes conflicting evidence in current literature 
describing the peculiar aspects of regional (e.g. venous vs arterial blood) differences 
in platelet reactivity motivated the endeavor to study the intracoronary platelet 
function using a whole blood Point-of-Care test based on the principle of impedance 
aggregometry (102-106). In particular, we aimed to assess on-treatment platelet 
reactivity in peripheral and coronary blood in a group of patients treated with dual 
antiplatelet therapy following p-PCI for STEMI. 
The role of coagulation in the onset and evolution of ACS has recently been the 
subject of various studies aimed to detect a possible causal relationship between the 
presence of systemic hypercoagulability state and clinical consequences. In this 
study, patients underwent dual antiplatelet therapy and anticoagulant therapy prior 
to the sample withdrawal, so the values obtained by Point-of-Care methods, in 
particular the Multiplate® aggregometer, were influenced by both acute clinical 
condition of the patient and antiplatelet drug therapy. Accordingly, we expected 
presence of ASPI-test and ADP-test AUC values below the normal range and we 
considered “Low responders” to antiplatelet therapy when an AUC value of ASPI-
test or ADP-test greater than or equal to a pre-established normal range. In our 
study; a greater tendency of low platelet reactivity in coronary blood, however 
differences between values of AUC of both ASPI-test and ADP-test in coronary 
blood and peripheral blood were not statistically significant. This appears more 
likely to be due to high antiplatelet drugs effect at plaque ulceration/thrombus site, 
where the hemostatic process is highly active at onset of STEMI.	
Our findings suggest that coronary arteries could provide an adequate and 
reliable site of blood sampling to study platelet function with MEA. Moreover, 
antiplatelet therapy during a STEMI seems to be equally effective in inhibiting 
platelet function in peripheral or in coronary blood. The results of our study are in 
line with previously published work by other groups that found similar results in 
platelet function measured in venous and in arterial blood (104-106). We found no 
correlation between platelet function and hematocrit (138). Likewise, there was no 
significant correlation between higher on-treatment reactivity and gender (139,140) 
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or cardiovascular risk factors - mainly diabetes - as previously reported (141,142). 
The most plausible explanation could be related to the relatively small sample size 
unsuitable to prove the existence of any such differences.  
In addition, the platelet reactivity in coronary blood was not significant 
inferior to that observed in peripheral blood. We detected a significant correlation 
between platelet activity in peripheral and in coronary blood, i.e. the presence of a 
linear correlation between the “low Aspirin responders” observed by the ASPI-test 
and the “low ADP receptor inhibitors responders” observed by the ADP test. 
Moreover, it has been observed that those who are low responders to acetylsalicylic 
acid tend to be low responders also to the ADP receptor inhibitors and vice versa, 
and who is sensitive to acetylsalicylic acid therapy with curtain to be sensitive to 
receptor inhibitors for ADP. These data remain a matter of debate, but could 
identify a subgroup of patients with "cross non-responsiveness" to the two drugs, 
which may have a worse prognosis in terms of clinical outcomes (e.g. acute or 
subacute thrombosis of the stent) compared to the group of subjects not responding 
to one of the two treatments and even more to the patients responsive to both drugs. 
The novelty of our study resides in measuring the platelet function in 
subjects taking Prasugrel and Ticagrelor, two drugs not taken into account by 
previous studies. In particular, we studied a group of controls and determined an 
“in-house” threshold (e.g. the lower limit of the normal range) both for the ASPI-
test and the ADP-test to identify patients with a reduced response to antiplatelet 
therapy (e.g. subjects with a platelet function in ASPI-test or ADP-test above the 
aforementioned cut-off). With that in mind, the prevalence of “low aspirin 
responders” was approximately 14% both in peripheral and in coronary blood, a 
similar number (11%) to that previously reported (104,143). The prevalence (38%) 
of “low thienopyridines responders” observed in our study, both in peripheral and 
in coronary blood, was in line with the data reported in literature to date (144). To 
come to the point, we observed the failure of responsiveness to antiplatelet 
treatment with P2Y12 inhibitors in at least one third of cases, at time of p-PCI. The 
most reasonable explanation may be the different route of administration of both 
types of drugs. In particular, being intravenous for aspirin and oral for ADP receptor 
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inhibitors, it could contribute to explain the major prevalence of low responders 
observed in both peripheral blood and coronary blood to ADP-test in compared to 
the ASPI test. In fact, it is likely that the bioavailability of aspirin, in terms of rapid 
onset of action and high plasma concentration, is greater than that of ADP receptor 
inhibitors. Remarkably, the prevalence of “low Prasugrel/Ticagrelor responders”, 
though smaller than that observed in patients taking Clopidogrel, was higher than 
previously reported (145,146). In our study, thienopyridines administrated during a 
STEMI underwent emergent p-PCI, appeared to be equally effective in inhibiting 
platelet function both in peripheral and in coronary blood. Moreover, all patients 
who exhibited higher on-treatment platelet reactivity in coronary blood also had 
higher on-treatment platelet reactivity in peripheral blood.  
In this study, we observed no correlation between platelet reactivity function 
and clinical outcome neither for in-hospital nor clinical outcomes at 1-year, most 
probably due to small size population of the study. The clinical significance of 
laboratory “aspirin and/or thienopyridines resistance” remains a matter of debate 
and larger studies are needed for in-depth assessment of any correlation between 
on–treatment platelet reactivity measured in coronary blood and clinical outcome. 
If a definitive close correlation will be established between platelet function in 
peripheral and/or coronary blood and possible clinical outcomes (e.g. intrastent 
thrombosis), all patients on antiplatelet therapy for acute coronary syndrome might 
benefit from a routine monitoring of the platelet activity in order to tailor the 
antiplatelet therapy to the patient’s test results and unique needs. In this regard, 
features such as the use of whole blood, automatic method, and bedside Point-of-
Care device would make MEA more suitable than the other platelet function assays. 
The possibility to measure the platelet function with a bedside Point-of-Care device 
could also play a crucial role in identifying patients with a high responsiveness to 
antiplatelet therapy and therefore at a higher risk for bleeding complications (147).  
Needleless to say, one very important issue to consider while comparing the 
results of different studies on platelet function assessment is the pre-analytic 
conditions of each study which can strongly influence the results (148-152). Such 
pre-analytic conditions include, but are not limited to, methods of sample 
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collection, temperature and anticoagulant used. Consequently, we set out to curb 
variability in pre-analytics between venous and arterial blood samples by following 
strict procedures in both the collection and the management of samples. In 
particular, trained personnel managed blind samples swiftly and each sample was 
managed at room temperature. The use of an “in-house” reference range established 
in a group of healthy individuals, whose samples were obtained and managed as 
mentioned above, contributed to reducing pre-analytic bias. 
Some limitations need to be acknowledged, the sample of patients enrolled 
while homogeneous, was too small to lose the significance of the differences that 
emerged in some comparisons (e.g. between ASPI-test values peripheral vs 
coronary or ADP-test values peripheral vs coronary blood). Moreover, despite 
impedance aggregometry test performed through MEA being a widely validated 
methodology in the study of platelet function in patients with coronary artery 
disease (153), it carries a high inter-individual variability that prevents 
standardization. Similarly, the citrate as anticoagulant in the tubes lacks 
standardization even though its use has been suggested in literature as a possible 
alternative way to draw samples for aggregometry (154,155). Finally, the direct 
comparison between peripheral and coronary blood could be affected by the ex vivo 
platelet activation in the latter setting. Young A et al. (156) have previously argued 
that this is not the case, but we cannot rule out this bias with certainty. 
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8- CONCLUSIONS 
The study observed that the overall platelet reactivity in coronary blood is 
lower than in peripheral blood, though without statistical significance. This more 
likely appears to be due to high antiplatelet drugs effect at plaque 
ulceration/thrombus site, where the hemostatic process is highly active at onset of 
STEMI. Larger studies are necessary to better evaluate these mechanisms in terms 
of pharmacodynamic, pharmacokinetic and receptor kinetic properties of 
antiplatelet agents.	
Antiplatelet therapy during a STEMI seems to be equally effective in 
inhibiting platelet function both in peripheral and in coronary blood. The other 
interesting data emerging from data processing is the high incidence (about 30%) 
of low response thienopyridine type antiplatelet drugs at the time of primary 
angioplasty. These results, moreover known for Clopidogrel, also include patients 
treated with Prasugrel and Ticagrelor.  An explanation of this phenomenon, which 
also involves very potent drugs, requires careful analysis of further studies. The 
significant direct correlation between platelet reactivity in peripheral and in 
coronary blood is still a matter of debate. Larger studies are needed for in-depth 
assessment of any correlation between on–treatment platelet reactivity measured in 
coronary blood and clinical outcome. 
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